Our Vision

Scopio is changing the standard of healthcare and revolutionizing first-line diagnostic testing by harnessing the power of computational photography and AI to image and analyze the morphology of cells at a scale that was never possible before, expediting access to life-saving treatments and improved patient outcomes.

Our Story

Scopio Labs was founded by two physicists and visionaries determined to push the boundaries of medicine and innovate in a way that would do some good in the world.

Early in their careers, Itai Hayut and Erez Na’aman dreamed of a collaboration. After witnessing medical practitioners in the hematology lab who still rely on analog, outdated, and labor-intensive practices using traditional microscopes and manual cell counts, they realized that with their backgrounds in physics, IT and medical device technology and the evolution of deep learning, they could use AI-powered analysis to bring microscopy and hematology into the digital age. All they needed was to find a scanner to digitize the slides, and the rest would fall into place.

But no such scanner existed, and so that’s where the Scopio story began.

The result is a series of innovations that brings high-quality data and advancements in deep learning to the practice of hematology, transforming the future of disease detection and diagnosis forever.


Scopio Labs CEO, ItaI Hayut

Itai Hayut

Co-Founder and CEO

Erez Naaman, Co-Founder of Scopio Labs

Erez Na'aman

Co-Founder and CTO

Guy Nathanzon, CFO for Scopio Labs

Guy Nathanzon


Iris Getz


Amir Farhi

Chief Commercial Officer

Shahar Karny

Chief Operating Officer
Chief Product Officer Amy Meitus MD

Amy Meitus MD

Chief Product Officer

Eran Small PhD

Chief Innovation Officer

Oren Harel


Lianne Trantz, VP of Marketing for Scopio Labs

Lianne Trantz

VP Marketing

Jordan Feder

VP Business Development

Tali Cohen



Corporate Announcements

February 23, 2023 : Scopio Labs Doubles Down on Digital Cell Morphology Go-To-Market Strategy in 2023. With recent appointment of Chief Commercial Officer Amir Farhi and global strategic partnerships, Scopio will be scaling up commercialization

September 8, 2022 Scopio Labs Launches World’s First Digital Application for Bone Marrow Aspirate Imaging and Review :  Scopio’s CE-Marked Full-Field Bone Marrow Aspirate™ Application provides an enhanced hematology workflow by utilizing AI and imaging of vast numbers of cells to overcome limitations of manual microscopy

July 20, 2022 : Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform Beckman Coulter, a global leader in clinical diagnostics, and Scopio Labs, a medtech company that develops AI-powered workflow solutions, announced today a worldwide partnership to accelerate adoption of Scopio’s next generation peripheral blood smear platforms.

June 9, 2022: Scopio Labs Awarded FDA Clearance for High Throughput Hematology Digital Cell Morphology Platform, Replacing Microscopes with Digitization. This is the company’s second FDA clearance, broadening its suite of fully digital platforms to cater to all lab sizes and networks

Feb 9, 2022: Scopio raises $50M to take a deeper look into our blood cells. The company’s ultra high quality and FDA-cleared imaging and AI analysis platforms enhance diagnostic capabilities and enable remote work

Sept 27, 2021: Scopio Labs Launches Full-Field Peripheral Blood Smear Application, Bringing End-to-End Digital Workflow to Hematology Labs to Transform Diagnostic Testing

Oct 21, 2020: FDA Clearance of Full Field PBS Application. The First Ever Solution to Enable Digitization and Analysis of Full Field Peripheral Blood Smears with Decision Support System (DSS) Tailored to Augment Hematology Diagnostics

Apr. 28, 2020: Scopio Labs Closes $16 Million Series B Round to Expand Commercial Rollout of Automated Microscopy Solutions. All-Digital AI-Powered Platform to Reduce Human Error, Connect Remote Experts, Increase Diagnostic Lab Reliability and Efficiency

Apr. 13, 2020: Scopio Labs Receives CE Mark for X100 Microscope and Decision Support System With Full Field Peripheral Blood Smear (PBS) Application. All-Digital Automated Scanning and AI-Powered Analysis Enables Precise and Comprehensive Diagnosis, Remote Consultation and Accelerated Results to Improve Care Outcomes